| 1 |
26736983 | A semi-mechanistic pharmacokinetic model of saquinavir combined with itraconazole in HIV-1-positive patients. | 2015 |
3 |
| 2 |
22971642 | Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice. | 2013 |
2 |
| 3 |
21906676 | Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement. | 2012 Jan |
1 |
| 4 |
22128044 | Protease inhibitor-associated QT interval prolongation. | 2011 Dec |
1 |
| 5 |
19864617 | Mechanistic insight from in silico pharmacokinetic experiments: roles of P-glycoprotein, Cyp3A4 enzymes, and microenvironments. | 2010 Feb |
1 |
| 6 |
19931478 | Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS. | 2010 Jan |
1 |
| 7 |
19381336 | Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers. | 2009 Mar |
1 |
| 8 |
19792991 | Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. | 2009 Oct |
2 |
| 9 |
19163953 | Mechanistic simulations explain paradoxical saquinavir metabolism during in vitro vectorial transport study. | 2008 |
1 |
| 10 |
17329995 | CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. | 2007 May |
1 |
| 11 |
16863481 | Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe. | 2006 Aug |
1 |
| 12 |
14718607 | Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. | 2004 Mar |
3 |
| 13 |
12790697 | Saquinavir: a review of its use in boosted regimens for treating HIV infection. | 2003 |
1 |
| 14 |
12949438 | Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology. | 2003 |
1 |
| 15 |
14651727 | Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. | 2003 Nov |
1 |
| 16 |
11824416 | CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. | 2002 Jan |
7 |
| 17 |
12047481 | Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. | 2002 Jun |
1 |
| 18 |
11336588 | Pharmacology and clinical experience with saquinavir. | 2001 Feb |
1 |
| 19 |
10926350 | Drug interactions with cisapride: clinical implications. | 2000 Jul |
1 |
| 20 |
10930961 | Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. | 2000 Aug |
1 |
| 21 |
10082072 | Drug interactions of HIV protease inhibitors. | 1999 Feb |
1 |
| 22 |
10215697 | First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers. | 1999 May |
1 |
| 23 |
9029057 | Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. | 1997 Feb |
4 |
| 24 |
9278209 | Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. | 1997 Aug |
2 |
| 25 |
9486958 | HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. | 1997 Dec |
2 |
| 26 |
10837554 | Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. | 1997 Sep 15 |
1 |